381 related articles for article (PubMed ID: 36216148)
21. Natural Killer Cell-Based Immunotherapy against Glioblastoma.
Morimoto T; Nakazawa T; Maeoka R; Nakagawa I; Tsujimura T; Matsuda R
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768432
[TBL] [Abstract][Full Text] [Related]
22. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Neagu MR; Reardon DA
Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
[TBL] [Abstract][Full Text] [Related]
23. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
Lin YJ; Mashouf LA; Lim M
Front Immunol; 2022; 13():817296. PubMed ID: 35265074
[TBL] [Abstract][Full Text] [Related]
24. Considerations for personalized neoantigen vaccination in Malignant glioma.
Dunn GP; Sherpa N; Manyanga J; Johanns TM
Adv Drug Deliv Rev; 2022 Jul; 186():114312. PubMed ID: 35487282
[TBL] [Abstract][Full Text] [Related]
25. Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators.
Segura-Collar B; Hiller-Vallina S; de Dios O; CaamaƱo-Moreno M; Mondejar-Ruescas L; Sepulveda-Sanchez JM; Gargini R
Acta Neuropathol Commun; 2023 May; 11(1):79. PubMed ID: 37165457
[TBL] [Abstract][Full Text] [Related]
26. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract][Full Text] [Related]
27. Research progress of neoantigens in gynecologic cancers.
Song Y; Zhang Y
Int Immunopharmacol; 2022 Nov; 112():109236. PubMed ID: 36113318
[TBL] [Abstract][Full Text] [Related]
28. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
[TBL] [Abstract][Full Text] [Related]
29. Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
Jindal V
Mol Neurobiol; 2018 Nov; 55(11):8236-8242. PubMed ID: 29524050
[TBL] [Abstract][Full Text] [Related]
30. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
33. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
34. Neoantigen-directed therapeutics in the clinic: where are we?
Lybaert L; Thielemans K; Feldman SA; van der Burg SH; Bogaert C; Ott PA
Trends Cancer; 2023 Jun; 9(6):503-519. PubMed ID: 37055237
[TBL] [Abstract][Full Text] [Related]
35. Neoantigens and their clinical applications in human gastrointestinal cancers.
Eshkiki ZS; Agah S; Tabaeian SP; Sedaghat M; Dana F; Talebi A; Akbari A
World J Surg Oncol; 2022 Sep; 20(1):321. PubMed ID: 36171610
[TBL] [Abstract][Full Text] [Related]
36. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Zheng Y; Fu Y; Wang PP; Ding ZY
Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
[TBL] [Abstract][Full Text] [Related]
37. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
Dong X; Ren J; Amoozgar Z; Lee S; Datta M; Roberge S; Duquette M; Fukumura D; Jain RK
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898734
[TBL] [Abstract][Full Text] [Related]
38. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
39. Emerging therapies for glioblastoma: current state and future directions.
Rong L; Li N; Zhang Z
J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
[TBL] [Abstract][Full Text] [Related]
40. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
Gargett T; Ebert LM; Truong NTH; Kollis PM; Sedivakova K; Yu W; Yeo ECF; Wittwer NL; Gliddon BL; Tea MN; Ormsby R; Poonnoose S; Nowicki J; Vittorio O; Ziegler DS; Pitson SM; Brown MP
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]